Effect of Size and Heterogeneity of Samples on Biomarker Discovery: Synthetic and Real Data Assessment by Di Camillo, Barbara et al.
Effect of Size and Heterogeneity of Samples on
Biomarker Discovery: Synthetic and Real Data
Assessment
Barbara Di Camillo
1, Tiziana Sanavia
1, Matteo Martini
1, Giuseppe Jurman
2, Francesco Sambo
1, Annalisa
Barla
3, Margherita Squillario
3, Cesare Furlanello
2, Gianna Toffolo
1, Claudio Cobelli
1*
1Information Engineering Department, University of Padova, Padova, Italy, 2Fondazione Bruno Kessler, Povo, Trento, Italy, 3Department of Computer and Information
Science, University of Genova, Genova, Italy
Abstract
Motivation: The identification of robust lists of molecular biomarkers related to a disease is a fundamental step for early
diagnosis and treatment. However, methodologies for the discovery of biomarkers using microarray data often provide
results with limited overlap. These differences are imputable to 1) dataset size (few subjects with respect to the number of
features); 2) heterogeneity of the disease; 3) heterogeneity of experimental protocols and computational pipelines
employed in the analysis. In this paper, we focus on the first two issues and assess, both on simulated (through an in silico
regulation network model) and real clinical datasets, the consistency of candidate biomarkers provided by a number of
different methods.
Methods: We extensively simulated the effect of heterogeneity characteristic of complex diseases on different sets of
microarray data. Heterogeneity was reproduced by simulating both intrinsic variability of the population and the alteration
of regulatory mechanisms. Population variability was simulated by modeling evolution of a pool of subjects; then, a subset
of them underwent alterations in regulatory mechanisms so as to mimic the disease state.
Results: The simulated data allowed us to outline advantages and drawbacks of different methods across multiple studies
and varying number of samples and to evaluate precision of feature selection on a benchmark with known biomarkers.
Although comparable classification accuracy was reached by different methods, the use of external cross-validation loops is
helpful in finding features with a higher degree of precision and stability. Application to real data confirmed these results.
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Introduction
In the last decade, transcriptome analysis performed with high-
throughput microarrays has experienced a huge diffusion and has
profoundly changed the approach to the study of complex
diseases. In an experimental design, the data typically come from
different subjects and phenotypes. The analysis of these data has
proven extremely useful for the identification of biomarker genes
and for the development of new physiologic hypotheses useful for
answering diagnostic, prognostic and functional questions. How-
ever, for complex diseases such as cancer, the high-throughput
analysis carried out in different laboratories and research centers
has given different results, with limited overlap or reduced
statistical significance [1,2]. These differences are matters of
important scientific discussions and, besides the different or poorly
reproducible experimental protocols and analysis pipelines [3–5],
are imputed to two main reasons:
1. Datasets often include small numbers of subjects (some tens)
with respect to the number of variables (tens of thousands of
genomic probes in human) [6,7];
2. The most complex pathologies, such as cancer, are heteroge-
neous and multifactorial, as a result of the alteration of multiple
regulatory pathways and of the interplay between different
genes and the environment, rather than referable to a single
dysfunctional gene like in monogenic diseases [8,9]. A
consequence of this is that data are characterized by many
correlated features; different features may thus be selected
under different settings.
Widely used methodologies for the identification of biomarkers
using microarray data are based on computing differential gene
expression by univariate statistical tests. Such approaches provide
information on the effects of specific genes as individual features,
whereas it is now widely recognized that the interplay between
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differentially expressed, might be extremely important to charac-
terize a disease status [10–11]. Machine learning algorithms are, in
principle, able to identify multivariate nonlinear combinations of
features and have thus the possibility to select a more complete set
of experimentally relevant gene features. In this context,
classification methods are often used to select biomarker genes
from microarray data. In a recent study [12], classification
performance of different methods was compared across different
microarray studies in terms of ability to select biomarkers
discriminating between two conditions. Besides reaching good
classification accuracy, obtaining stable list of biomarkers is critical
both to understand the results from a biological point of view and
to gain sufficient reliability on potential targets of clinical and
pharmaceutical applications. The stability issue in feature selection
has received much attention recently [13–16]. In a recent
contribution, He and Yu [17] review existing stable feature
selection methods for biomarker discovery.
As shown in [18], biomarker stability and accuracy are
associated to task difficulty, and higher stability is found for
higher accuracy. However, it is in principle possible to have a lack
of stability due to the presence of many highly correlated features,
even with accuracy equal to one. A first contribution of this work is
the comparison of different classification methods in terms of
consistency of lists of candidate biomarkers and classification
accuracy. To this purpose, three real microarray datasets
monitoring breast cancer patients with positive and negative
estrogen receptor status are used; we compare biomarker lists from
the three datasets as well as sets of sub-lists of different sample size
obtained from each dataset.
A slightly different issue, although related with list stability, is
the precision of biomarker identification, i.e. the ability to select
true biomarkers, defined as features biologically related to the
physiological or clinical condition under study as cause or effect of
it. A second contribution of our work is the generation of a
simulated dataset to assess alternative methods’ performance
across multiple studies and varying number of samples, and to
evaluate precision of feature selection on a benchmark with known
biomarkers. We extensively simulate the effect of heterogeneity
and variability on different sets of synthetic microarray data
consisting of two balanced groups of 50, 20, 15 or 10 subjects.
Sample heterogeneity characteristic of complex diseases is
reproduced within the same group by simulating both intrinsic
variability of the population and the alteration of regulatory
mechanisms induced by the disease. Population variability is
simulated by modeling evolution of a pool of subjects in terms of
pairing, mutation and selection in order to generate individuals
characterized by different genotypes. Then, a subset of this
population undergoes alterations in regulatory mechanisms so to
mimic the disease state; these perturbations are slightly different
across the patients in the diseased group, so to reflect the lack of
homogeneity among patients that is typically reported in the
literature for complex diseases [8].
Different methods for binary classification and feature weighting
and ranking are applied to both simulated and real data. In
particular, the classical Support Vector Machine algorithm (SVM)
[19] is used in its linear and Gaussian kernel versions, and the
SVM weights are used for feature ranking. As an alternative, I-
Relief [20] is also used as the feature ranking algorithm coupled
with linear SVM. One method of totally different nature is also
applied: the Spectral Regression version of the Discriminant
Analysis algorithm (SRDA) both as a classifier and a feature
weighting algorithm [21]. All methods make use of the Entropy-
based version of the classical Recursive Feature Elimination
procedure as ranking schema [22,23]. In all experiments, external
cross-validation loops with separate training and test phases are
employed to avoid overfitting effects such as selection bias [24].
Results are also compared with those obtained by using SAM, a
widely applied variant of univariate statistical t-test [25].
Methods
Simulation of population variability
Each subject in the dataset was modeled by a regulatory
network of N=10000 genes, based on the simulator described in
[26], using default parameter settings. The topology is character-
ized by the connectivity matrix W, with weights wij different from
zero if gene-product j directly affects the expression of gene i. The
sign and the magnitude of wij indicate the sign and the strength of
the regulation. Differential equations were used to model the
dynamics of transcription and degradation as continuous variables
and to describe transcription delay with different time constants
for each gene (see Text S1 for further details).
In molecular biology, transcription factors and enhancers are
proteins that bind to specific DNA sequences and can regulate
transcription of a gene by respectively activating/blocking the
transcription and tuning the quantity of RNA transcribed in a unit
of time. Loosely speaking, weights wij of the connectivity matrix W
can be interpreted as the affinity of the genome specific sequences
for a transcription factor or an enhancer j, regulating expression of
a gene i. Since weights wij can in principle be mapped to specific
nucleotide sequences in the genome, W can be interpreted as part
of the genotype of the subject. Moreover, since each network is
characterized by a finite number of attractors, reachable from a
specific set of initial conditions and/or external stimuli, each
attractor can be interpreted as the phenotype of an individual in a
particular environmental condition.
Following these concepts, evolution of a population of M=1000
individuals was simulated using a procedure similar to the one
described in [27]. In summary, subjects were modeled as
regulatory networks of N=10000 nodes characterized by a
specific genotype (the connectivity matrix W with weights wij)
and a specific phenotype (the system attractors). Given specific
initial conditions (i.e. environment condition that we consider fixed
for the purpose of this work), the initial population at generation 1
consisted of M individuals with identical connectivity matrix W
and with N dimensional vectors of expression values obtained by
considering the steady state reached by the system. Gene specific
kinetic parameters ai and bi were sampled from Gaussian
distributions with means ma, mb and standard deviations sa, sb.
For each subject, ma and mb were set to 20 and 0.2, respectively,
whereas sa and sb were sampled from a Gaussian distribution
with means 0.5 and 0.02 and standard deviations equal to 0.075
and 0.0025, respectively. Parameters values (Text S1, Equations 1
and 2) were empirically chosen so to generate in silico data with
statistical distribution similar to those observed on the real
datasets.
To introduce genotype variability in the population, subsequent
generations were produced by iteration of three steps: random
pairing of individuals, mutation of a randomly chosen subset of
subjects and selection of the surviving subjects. For computational
reasons, these three steps were applied only to a sub-network of
size N=900, indicated as W900 in the following, which was
constrained to be not connected to any of the other 9100 nodes in
the network. Each step is described in detail in what follows.
a. Pairing. Offspring was created by randomly selecting two
parents among the current population of M individuals and
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each parent with equal probability.
b. Mutation. Mutation was simulated by changing each nonzero
wij (which, by simulation, resulted equal to 1619 elements on a
matrix of 9006900=810000 elements) with probability 0.025/
1619. The new value of each mutated wij was sampled from a
Gaussian distribution with mean and standard deviation equal to 0
and 1, respectively. Therefore, at each iteration, each subject
mutated with probability 0.025.
c. Selection. Assuming, in a naı ¨ve simplification of reality, that
individuals behaved as haploid organisms and that the initial
phenotype was essential for survival, subjects with at least one
mutated wij were allowed to survive only if their phenotype did not
change with respect to the original population. In practice, we
calculated the Euclidean distance between the expression profile of
each mutated subject (the N dimensional vector of gene expression
values at steady state) and the average expression profile of subjects
at generation 1; if Euclidean distance exceeded the value of 0.81
(corresponding to the percentile 99.5 of the observed distances) the
subject was eliminated, otherwise he/she survived. At each
generation, M individuals were generated, independently of the
number of parents survived in the previous generation. Evolution
proceeded for a time sufficient to have a final population of M
subjects with the same phenotype but different genotype, i.e. 150
generations (Figure S1).
Noise was added to expression data of the 10000 genes in the
1000 subjects as additive Gaussian noise with mean 0 and
standard deviation sampled from the distribution of within-groups
error variance in real datasets (paragraph 2.3), as described in
[28]. In particular, the error variance associated to genes was
approximated by a lognormal distribution with mean 0.22 and
standard deviation 0.35.
Simulated data
Once the base population was simulated, two groups, each of
500 subjects, were defined. The pathological condition was
simulated by knocking out or down six target hubs, defined as
those genes with the highest out-degree and expression value at
steady state higher than 0.88, so that their knock-out (down)
achieved an effect. The knock-out of gene j was simulated by
setting to 0 its expression and all the elements of row j in matrix W.
Consistently, the knock-down of gene j was simulated by halving
its value and all the elements of row j in matrix W. Diseased
subjects had 4, 5 or 6 genes belonging to W900 that were knocked
out or down. The proportion of subjects with 4, 5 or 6 genes
affected was set equal to 1/3, 1/3, 1/3, respectively. For each
gene, the proportion of subjects affected by knock-out and knock-
down was set equal to 1/3 and 2/3, respectively. Figure 1 displays
the diseased group variability in terms of histogram of the
Euclidean distance between the steady states of the original and
the diseased population. The variability rises from both the
intrinsic population variability, i.e. the different connectivity
weights wij in W900, and the heterogeneity of the disease.
Comparison between simulated and Affymetrix data (GSE2990,
see below) showed that the datasets have very similar distribution
(Wilcoxon test p-value equal to 0.9).
The putative biomarkers were defined as those genes directly or
indirectly regulated by at least one of the six hubs, having
expression modified by the knock-out (down). This resulted in 155
biomarkers on a total of 10000 features.
To consider the effect of sample size, we partitioned the two
groups of 500 healthy and 500 diseased subjects into 4 sets of 10
balanced non-overlapping datasets of size 50, 20, 15 or 10 subjects
per group (10 datasets for each case study), for a total of 40
simulated datasets.
Real data
Publicly available data from three breast cancer microarray
studies were collected from Gene Expression Omnibus repository
(GEO) with accession numbers: GSE2990 [29], GSE3494 [30]
and GSE7390 [31].
Datasets were all hybridized using Affymetrix U133 Gene-
chips
TM (HG-U133A). Samples that have known estrogen-receptor
(ER) status were selected so to have balanced groups (ER+ and
ER2), homogeneous with respect to characteristics such as age,
tumor size and histological grade. We chose to investigate the ER
status because it is always assessed in breast biopsies, therefore it is
very often present among the clinical/pathological information
given with the datasets. Moreover, the assessment of the ER status is
important to divide breast cancer into molecular classes and to treat
cancer with the hormone blocking therapy [32]. Since there are
subgroups of samples belonging to multiple datasets, redundant
subjects were removed. The resulting datasets are characterized by
22207 features (probe sets) and 66 subjects for GSE2990 (33 ER+,
33 ER2), 50 subjects for GSE3494 (25 ER+,2 5E R 2)a n d9 2
subjects for GSE7390 (46 ER+,4 6E R 2). Comparison among the
three datasets allowed assessing list stability in a real case study. To
assess list stability within dataset, thus not accounting for
experimental setup variability, and to compare the effect of sample
size with simulated data, 20 subjects per ER status were repeatedly
sampled from datasets GSE2990 and GSE7390 to set up smaller
balanced datasets (10 datasets for each case study). Gene expression
intensity signal was derived and normalized independently for each
dataset using the robust multiarray average (RMA) algorithm [33].
Probe sets related to the estrogen receptor (ESR1) were removed
from all datasets, since ESR1 is the gene more directly associated
with ER status and can mask other potential descriptors of the
underlying pathophysiology [34].
Biomarker discovery methods
Support Vector Machine (SVM). Support Vector Machines
[19] are a set of supervised learning methods used for
classification, in principle able to identify nonlinear features thus
providing a more complete set of relevant genes. They were used
here with linear (LSVM) and Gaussian kernel (GSVM). The
tuning phase required the identification of the optimal value of the
regularization parameter c (the trade-off between empirical error
and smoothness of the solution) and, for the Gaussian kernel, of
the bandwidth s.
Iterative-Relief and SVM (IRSVM). Iterative Relief [20] is
a feature selection/ranking algorithm that solves a convex
optimization problem with a margin-based objective function in
Figure 1. Variability of the diseased population. Histogram of the
Euclidean distance between the steady states of the diseased
population with respect to the original phenotype.
doi:10.1371/journal.pone.0032200.g001
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Relief can be used by an independent classifier: in our case, we
used it together with linear SVM. The only required parameter to
set is the bandwidth s of the internal kernel.
Spectral Regression Discriminant Analysis (SRDA).
SRDA algorithm embeds the classical Discriminant Analysis into
a regression framework through the use of spectral graph analysis
[21]. Thisimproves computational efficiency by solving only a set of
regularizedleastsquaresproblemswithout eigenvector computation
involved. Moreover, the score attributed to each feature can be
interpreted as a feature weight, allowing directly feature ranking.
The regularization value a is the only parameter we had to tune.
Parameter Tuning. For GSVM, IRSVM and SRDA,
parameter tuning was performed through a preliminary 3-fold
cross-validation (without feature ranking) run for a set of possible
parameter values.
Bootstrap. The four methods, LSVM, GSVM, IRSVM and
SRDA, were used both in single cross-validation and in a Monte
Carlo bootstrap resampling schema with B=100 external training/
testsplitswith3-fold cross-validationasinternalresampling(methods
named as LSVM_B, GSVM_B, IRSVM_B and SRDA_B in the
following). This strategy has been proved to be an effective
countermeasure against unwanted selection bias effects [23,24].
Ranking and selection. In the four aforementioned
methods, the Entropy-based Recursive Feature Elimination
(ERFE) procedure was used as the ranking schema [22].
Starting from the classical RFE algorithm [35], ERFE adaptively
discards a subset of the least informative features according to an
entropy measure of the distribution of the weights generated by
the feature weighting schema. This guarantees a relevant speed-up
of the ranking procedure without performance degradation. The
optimal number of features was chosen in correspondence to the
minimum classification error estimate.
Statistical analysis of Microarrays (SAM). The SAM test
[25] is a widely used univariate statistical test for the identification
of differentially expressed genes from microarray data. This
variant of the t-test accounts for the non Gaussian distribution of
data. SAM uses a resampling procedure to derive the null
hypothesis distribution and the false discovery rate (FDR) to
account for multiple testing [36]. In this study, a FDR=5% was
used to select features after a ranking based on their p-value.
Algorithm evaluation
Algorithm performance was evaluated in terms of the ability to
select true biomarkers, to provide stable lists of biomarkers and to
accurately classify the subjects.
The ability to select the true biomarkers was evaluated in term
of precision (number of true positives divided by the number of
selected features) obtained by the different methods according to
their choice of the optimal number of features. The area under the
precision vs. recall (number of true positives divided by the number
of true biomarkers) curve was also considered to outline the ability
of the different methods to rank the features, a task related with the
ability to select the true biomarkers.
To evaluate the ability of the different methods to provide stable
lists of biomarkers, the algebraic stability indicator derived by
Canberra distance was used [15]. In particular, given two ordered
lists T1 and T2 of p ranked features, the Canberra distance
between them is defined as:
Ca T1,T2 ðÞ ~
X p
i~1
t1 i ðÞ {t2 i ðÞ jj
t1 i ðÞ zt2 i ðÞ
ð1Þ
where t1(i) and t2(i) indicate the rank, i.e. the position, of feature i
in the ordered lists T1 and T2, respectively. The stability indicator
for a given set of lists was computed as the mean of the Canberra
distances between pairs of lists in the set, normalized by its
expected value on the whole permutation group on p features: the
obtained value ranges then between 0 (maximal stability) and 1.4
(maximal instability), with 1 as the case of randomly generated
lists. A different extension based on quotients of permutation
groups allowed comparing lists T1 and T2 of different length l1, l2:
Ca T1,T2 ðÞ ~
1
p{l1 ðÞ !: p{l2 ðÞ !
X
C1[S1
X
C2[S2
Ca C1,C2 ðÞ ð 2Þ
where p is the total number of analyzed features and Cj (j=1,2)
belong to the set Sj of all the lists having the first lj features ordered
as in Tj and the remaining (p–lj) elements ordered in all the (p–lj)!
possible combinations. This is called the complete version of the
partial lists distance: neglecting its component depending only on
the discarded features we ended up with a different measure
(called core distance) better tailored to highlight variations on
partial short lists [37]. Full statements and proofs of the
mathematical properties of the Canberra distance can be found
in [38].
The Matthews correlation coefficient, MCC [39], was used as a
measure of the quality of binary classifications. The MCC can be
calculated directly from the confusion matrix using the formula:
MCC~
TP:TN{FP:FN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TPzFP ðÞ TPzFN ðÞ TNzFP ðÞ TNzFN ðÞ
p ð3Þ
In this equation, TP is the number of true positive, TN the
number of true negative, FP the number of false positive and FN
the number of false negative subjects.
Statistical significance of the comparison between each method
and its bootstrap variant was assessed using Wilcoxon signed ranks
test with significance level a equal to 0.05. Differences among the
four multivariate feature selection methods in their bootstrap
variant were assessed using Friedman test (a=0.05), followed, if
significant, by Wilcoxon signed ranks test to examine between
which methods the differences actually occur, with a significance
level a equal to 0.05/6=0.0083 to correct for multiple testing.
Finally, SAM was compared with the other eight methods using
Wilcoxon signed ranks test with a significance level a equal to
0.05/8=0.00625 to correct for multiple testing.
Results
Simulated data
Application of the nine biomarker discovery methods on the
forty simulated datasets provides information on precision of
feature selection, stability of biomarker lists and classification
accuracy.
Feature selection. Figure 2 shows boxplots of precision,
obtained by the different methods according to their choice of the
optimal number of features. Feature selection results show that
bootstrap resampling schema leads to an improvement in terms of
precision, statistically significant when the sample size decreases.
In particular, with 20, 15 and 10 subjects per group, bootstrap
improves precision of 1.5, 1.4 and 2 fold change, respectively
(average improvement across the four different classification
methods). Differences between bootstrap and non-bootstrap
approach are statistically significant (p-value lower than 0.05,
Wilcoxon signed ranks test) for LSVM and GSVM with 20
Sample Heterogeneity Effect on Biomarker Discovery
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group, for all methods but LSVM with 10 subjects per group. In
Figure 2, the interquartile range of the number of selected features
is also reported. Interestingly, with less than 50 subjects per group,
the bootstrap approaches have the tendency to select a lower
number of features.
There are no appreciable differences among different bootstrap
methods in terms of precision (Friedman test p-value always above
0.05 for every sample size). In the case of 50 subjects per group,
SAM detects differentially expressed features with average
precision comparable to that obtained by the other methods, but
GSVM, IRSVM and IRSVM_B, which perform statistically
significantly better than SAM (p-value equal to 0.002, 0.006, 0.006
respectively, Wilcoxon signed ranks test). With 20 subjects per
group, SAM is not able to select any gene with FDR lower than
0.05 in six datasets, whereas in the remaining four, it selects in
average 50 features with high precision (0.85 in average). In these
latter cases, SAM performs statistically significantly better than
LSVM (p-value=0.004) and SRDA (p-value=0.006), i.e. two
methods without the bootstrap approach. Finally, with less than 20
subject per group, SAM is not able to select any gene in any of the
dataset with FDR lower than 0.05; thus we could not report any
result in these latter two cases.
A slightly different task, although related to feature selection, is
feature ranking. In principle, a method could rank features
properly, but fail to select the optimal number of features. Areas
under the precision vs. recall curves (AUC) obtained by ranking
features (Figure 3) show appreciable differences between methods.
Bootstrap methods perform better than their standard variants for
datasets of size 50, 20 and 15, for all methods (p-value always
below 0.005) but GSVM. For datasets of size 10, only SRDA_B
improves with respect to SRDA (p-value=0.01). With datasets of
50, 20 and 15 subjects per class, IRSVM_B is the best performing
algorithms (Friedman test gave p-value lower than 0.004 for every
sample size and Wilcoxon signed ranks test gave p-value lower
than 0.003 for every comparison between IRSVM_B and the
other bootstrap methods). With 10 subjects per group, all
multivariate methods show AUC below 0.5, without statistically
significant differences among them.
With 50 and 20 subjects per group, a simple univariate test such
as SAM is able to rank differentially expressed features with
performance comparable to multivariate methods such as LSVM,
GSVM, SRDA and their bootstrap versions, but not to IRSVM
and IRSVM_B that perform better (p-values equal to 0.002 for
both tests). However, when the number of subjects is lower than
20, SAM performance in feature ranking dramatically drops with
respect to classification based methods (p-value lower than 0.002
for all comparisons but GSVM and GSVM_B). This behavior is
consistent with the inability of SAM to select any feature with 15
and 10 subjects per group.
Feature stability. The ability of the various methods to
select the same features across different datasets is depicted in
Figure 4, where the boxplots of the core Canberra distance
(Equation 2) of the lists of selected features are shown. The
distance between the ranked lists increases for all the methods
when the number of subjects per group decreases. Results are
consistent with those obtained for feature selection: the bootstrap
resampling schema leads to an improvement in list stability,
statistically significant when sample size decreases. In particular,
differences are statistically significant for LSVM, SRDA and
IRSVM with 20 subjects per group (p-value always lower than
0.036), for LSVM, GSVM and IRSVM with 15 subjects per group
(p-value always lower than 0.033), for all methods with 10 subjects
per group (p-value always lower than 0.001). Among bootstrap
approaches, IRSVM_B is the best performing method in terms of
list stability, when 20 subjects per group are available; LSVM_B
performs as IRSVM_B in the case of 15 subjects per group;
GSVM_B performs as IRSVM_B in the case of 10 subjects per
group (Friedman test gave p-value lower than 10
211 for sample
Figure 2. Precision of feature selection on simulated data.
Boxplots of precision corresponding to the optimal number of features
chosen by different methods when 50, 20, 15 or 10 subjects per group
are available. A star highlights the significant differences between pair
of bootstrap and non-bootstrap approaches (p-value lower than 0.05,
Wilcoxon test). The interquartile range of the number of selected
features is also reported below each boxplot.
doi:10.1371/journal.pone.0032200.g002
Figure 3. Evaluation of feature ranking on simulated data.
Boxplots of area under the precision vs. recall curves obtained by
ranking features according to the different methods, when 50, 20, 15 or
10 subjects per group are available.
doi:10.1371/journal.pone.0032200.g003
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than 0.001 for every significant pairwise comparison).
In the case of 50 subjects per group, SAM shows list stability
comparable to the one obtained by the other methods. With 20
subjects per group, SAM is as good as IRSVM_B; however, results
are limited to the four datasets for which SAM was able to select
features below the 0.05 FDR threshold. As for feature selection,
with less than 20 subjects per group we do not report any results
since SAM was not able to select any gene in any of the dataset.
Classification Accuracy. Bootstrap approach also improves
classification accuracy (Table 1): with 50 subjects per group
LSVM_B and IRSVM_B perform better than their standard
versions (p-value equal to 0.019 and 0.007, respectively); with 20
subjects per group GSVM_B and SRDA_B perform better than
their standard versions (p-value equal to 0.030 and 0.025,
respectively); with 15 subjects per group LSVM_B, GSVM_B
and SRDA_B perform better than their standard versions (p-value
equal to 0.031, 0.031 and 0.016, respectively). All bootstrap
classification methods perform equally well (Friedman test p-values
always above 0.15 for every sample size) in terms of classification
accuracy.. SAM was excluded from this part of the analysis.
Real Data
Application of the various methods on breast cancer data
provides information on list stability and classification accuracy.
Results on dataset GSE3494 are not shown since none of the
different methods gave good accuracy (MCC always below 0.4).
On the other two datasets, results confirmed those obtained by
simulated data. In particular, bootstrap resampling schema leads
to an improvement in list stability (Figure 5), appreciable both
when the complete datasets GSE2990 and GSE7390 are
compared and when 20 subjects per group are repeatedly sampled
from each dataset, for a total of 10 resampled dataset for each of
the original datasets.
Differences between bootstrap and standard approach are
statistically significant for every method (p-value always lower than
0.002) with dataset GSE2990 and for LSVM and GSVM with
dataset GSE7390.
In terms of stability, SAM performance is poor: when 20
subjects per group are repeatedly sampled from each dataset the
core Canberra distance between lists of biomarkers ranges
between 0.04 and 0.37 (average 0.27) for GSE2990 and between
0.13 and 0.31 (average 0.22) for GSE7390; on the other hand,
between the complete datasets (GSE2990 vs. GSE7390) the core
Canberra distance is equal to 0.63. SAM results are not shown in
Figure 5 to avoid masking the differences among the other
methods.
The MCC obtained using different methods on real datasets is
shown in Table 2. The first two columns report the MCC for
GSE2990 and GSE7390, respectively, when 20 subjects per group
are repeatedly sampled from each dataset. The third and fourth
columns of Table 2 report the MCC obtained using the complete
datasets GSE2990 and GSE7390. Results are comparable to those
obtained using simulated data. Bootstrap approach improves
classification accuracy on dataset 7390 for all methods (p-value
equal to 0.02, 0.04, 0.001, 0.03 for LSVM_B, GSVM_B,
SRDA_B and IRSVM_B, respectively, with respect to their
standard version), whereas, with dataset 2990, the differences
between bootstrap and standard approaches are not statistically
significant. It is confirmed the tendency of the bootstrap
approaches to select a lower number of features. As observed
with simulated data, all bootstrap classification methods perform
equally well in terms of classification accuracy (Friedman test p-
values always above 0.06 on both the datasets).
To improve our confidence in the biological meaningfulness of
the results obtained with real data, the functional annotation of the
selected genes was considered. In particular, we considered: 1) the
intersection of the lists obtained by the four bootstrap methods on
datasets GSE2990 and GSE7390; 2) the intersection of the lists
obtained by IRSVM_B on datasets GSE2990 and GSE7390. The
two lists of genes and the results of enrichment analysis are
available in Text S2.
Discussion
The identification of an appropriate and robust biomarker
signature of a disease is a fundamental step for early diagnosis and
Figure 4. Evaluation of feature stability on simulated data.
Boxplots of the core Canberra distance between lists of selected
features obtained using different methods when 50, 20, 15 or 10
subjects per group are available. A star highlights the significant
differences between pair of bootstrap and non-bootstrap approaches
(p-value lower than 0.05, Wilcoxon test).
doi:10.1371/journal.pone.0032200.g004
Table 1. MCC corresponding to the optimal number of
features obtained using different methods - simulated data.
50 20 15 10
LSVM 0.73 (0.62, 0.82) 0.69 (0.51, 0.93) 0.73 (0.60, 0.88) 0.70 (0.60, 0.82)
LSVM_B 0.77 (0.65, 0.87) 0.74 (0.54, 0.95) 0.80 (0.68, 0.94) 0.73 (0.64, 0.83)
GSVM 0.78 (0.70, 0.87) 0.76 (0.62, 0.91) 0.81 (0.72, 0.89) 0.73 (0.66, 0.80)
GSVM_B 0.80 (0.65, 0.92) 0.81 (0.62, 0.95) 0.83 (0.66, 0.94) 0.71 (0.64, 0.86)
SRDA 0.75 (0.66, 0.84) 0.72 (0.61, 0.93) 0.74 (0.61, 0.87) 0.69 (0.60, 0.80)
SRDA_B 0.77 (0.67, 0.85) 0.74 (0.59, 0.96) 0.75 (0.60, 0.94) 0.73 (0.61, 0.83)
IRSVM 0.77 (0.66, 0.84) 0.83 (0.61, 0.94) 0.77 (0.67, 0.85) 0.65 (0.60, 0.80)
IRSVM_B 0.81 (0.67, 0.92) 0.72 (0.50, 0.95) 0.80 (0.64, 0.94) 0.69 (0.51, 0.86)
Average MCC obtained when 50, 20, 15 or 10 subjects per group are available.
Range of values is indicated in parenthesis.
doi:10.1371/journal.pone.0032200.t001
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32200treatment. However, for complex diseases such as cancer, high
throughput analysis carried out in different research centers may
exhibit poor reproducibility, with limited overlap or reduced
statistical significance. The results of the MAQC-II study address
in a comprehensive analysis this issue on real datasets by
comparing methods and procedures between data analysis teams
[18]. Here we have further explored the effect of the intrinsic
complexity of the task.
A first contribution of this work is the comparison of different
classification methods applied on real microarray datasets, in
terms of consistency of lists of candidate biomarkers and
classification accuracy. A second contribution of our work is the
generation of a simulated dataset to extensively assess average
method performance on a large number of studies and
experimental conditions, and to evaluate precision and feature
ranking performance on a benchmark with known biomarkers.
Heterogeneity of samples in each group is obtained by simulating
both intrinsic variability of the population and heterogeneity of the
disease. Despite its simplicity with respect to real systems, the
simulator provides a versatile test bed to assess a wide spectrum of
methodologies. The dataset is available upon request (ba
rbara.dicamillo@dei.unipd.it).
Results on simulated data show that when some tens of subjects
are available per group, performance of different methods are
comparable. However, when available subjects are equal or lower
than 20, bootstrap resampling schema leads to an improvement in
the precision of the selected features and list stability. Bootstrap
approach slightly improves also classification accuracy when 50,
20 or 15 subjects per group are available. Among the different
methods here considered, IRSVM_B provides the best combina-
tion of feature ranking and biomarker stability; moreover, it
reaches the best average performance also in terms of classification
accuracy.
In the case of 50 subjects per group, a simple univariate test
such as SAM shows performance comparable to that obtained by
the other methods. With 20 subjects per group, SAM performance
strongly depends on the dataset: on the simulated data, for
example, SAM is not able to select any gene with FDR lower than
0.05 in six datasets, whereas in the remaining four, it selects in
average 50 features with high precision (0.85 in average) and
stability comparable to the one obtained using IRSVM_B,
although this latter outperforms SAM in feature ranking. Finally,
with less than 20 subjects per group, SAM performance
dramatically drops with respect to classification based methods.
With real data, only list stability and classification accuracy can
be assessed. In both cases, results of classification methods tightly
resemble those obtained with simulated data.
In conclusion, our analysis confirms the MAQC-II indication
that comparably good classification accuracy can be reached by
different methods on the same task, provided that a valid Data
Analysis Plan is adopted [18]. Furthermore, we found a systematic
improvement due to bootstrap in selecting features with a high
degree of precision and stability. Overall, the crucial factor
affecting list stability seems to be that the classification task is
under constrained. When additional information is present on the
relationships between genes, this information could be used to
improve the stability with respect to the features of the classifiers.
The basic idea of this strategy would be to take into account the
complex gene relationships, instead of considering genes as
independent features. In future works, we plan to compare the
Figure 5. Evaluation of feature stability on real data. Boxplots of
the core Canberra distance between lists of selected features provided
by different classification methods when 20 subjects per group are
repeatedly sampled from GSE2990 (upper panel) and GSE7390 (middle
panel) datasets. A star highlights the significant differences between
pair of bootstrap and non-bootstrap approaches (p-value lower than
0.05, Wilcoxon test). The interquartile range of the number of selected
features is reported below each boxplot. The core Canberra distances
between lists of biomarkers provided by different methods on the
complete GSE2990 vs. GSE7390 datasets are shown in the lower panel
together with the number of selected features in each dataset.
doi:10.1371/journal.pone.0032200.g005
Table 2. MCC corresponding to the optimal number of
features obtained using different methods – real data.
GSE2990 20
subjects
GSE7390 20
subjects GSE2990 GSE7390
LSVM 0.64 (0.61, 0.69) 0.77 (0.61, 0.90) 0.60 0.79
LSVM_B 0.65 (0.51, 0.77) 0.81 (0.58, 0.91) 0.68 0.81
GSVM 0.62 (0.59, 0.64) 0.73 (0.60, 0.83) 0.59 0.74
GSVM_B 0.65 (0.60, 0.71) 0.78 (0.61, 0.91) 0.61 0.77
SRDA 0.63 (0.61, 0.66) 0.74 (0.62, 0.85) 0.50 0.78
SRDA_B 0.67 (0.61, 0.78) 0.83 (0.66, 0.90) 0.67 0.77
IRSVM 0.62 (0.47, 0.69) 0.80 (0.65, 0.91) 0.60 0.78
IRSVM_B 0.67 (0.58, 0.82) 0.82 (0.62, 0.91) 0.67 0.81
Average MCC obtained when 20 subjects per group are available, sampled from
datasets GSE2990 and GSE7390 MCC (range of values is indicated in
parenthesis), and obtained on the complete datasets GSE2990 and GSE7390.
doi:10.1371/journal.pone.0032200.t002
Sample Heterogeneity Effect on Biomarker Discovery
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32200use of different biological information from genomic databases in
the learning process by integrating different prior knowledge like
functional annotations, protein-protein interactions, and expres-
sion correlation among genes.
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